Stocks › GLUE
Monte Rosa Therapeutics GLUE
US equityMarket cap rank #3349
$8.64 −$0.27 (-3.03%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $8.64 0.00%
Open$8.73
Prev close$8.91
Day range$8.48 – $9.04
Volume2.52M
Market cap$738.29M
P/E (TTM)–
Dividend yield–
GLUE Stock News
Headlines matching Monte Rosa Therapeutics or the GLUE ticker, most recent first.
- Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Cuts Target Price to $28 Negative
- Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)
- J.P. Morgan Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Cuts Target Price to $27 Negative
- Jefferies Initiates Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Announces Target Price $25
- Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $35
- Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $35 Positive
- Wells Fargo Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $29
- Wedbush Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $37
- J.P. Morgan Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $31 Positive
- H.C. Wainwright Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $25
- Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $28
- Wells Fargo Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Cuts Target Price to $25 Negative
- Jefferies Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Cuts Target Price to $15 Negative
- Piper Sandler Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $37
- Analysts Are Bullish on Top Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Sagimet Biosciences, Inc. Class A (SGMT) Positive
No comments yet — be the first to weigh in on GLUE.
Sign in to join the discussion.